Jordi Sierra Gil-rekin lankidetzan egindako argitalpenak (17)

2019

  1. Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 683-694

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

2006

  1. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183

  2. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2005

  1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)

    Clinical Cancer Research, Vol. 11, Núm. 21, pp. 7757-7763

  2. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

    Annals of Oncology, Vol. 16, Núm. 4, pp. 625-633

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

2003

  1. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group

    Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151

2002

  1. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant

    Bone Marrow Transplantation, Vol. 30, Núm. 2, pp. 63-68

2001

  1. Allogeneic transplantation of CD34+ -selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood tranplantation

    Bone Marrow Transplantation, Vol. 28, Núm. 4, pp. 349-354

  2. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens

    Bone Marrow Transplantation, Vol. 27, Núm. 4, pp. 405-412

  3. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    Journal of Clinical Oncology, Vol. 19, Núm. 5, pp. 1395-1404

  4. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

    British Journal of Haematology, Vol. 114, Núm. 3, pp. 544-550

1997

  1. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL-TAMO cooperative group

    Bone Marrow Transplantation, Vol. 20, Núm. 4, pp. 283-288

  2. Trasplante alogénico de progenitores hemopoyéticos de sangre periférica no manipulados: Experiencia española de 79 casos

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 42-43

1994

  1. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the spanish cooperative group GEL/TAMO

    Bone Marrow Transplantation, Vol. 14, Núm. 2, pp. 279-286